It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Actinobacteria obtained from the least explored Indian regions were studied for their ability to suppress meningitis-causing bacteria in nanoparticle form. Drug-resistant bacteria and long-term treatment with different medications make meningitis control complicated. Thus, new meningitis drugs are required to combat MDR bacteria. In this study, secondary metabolites isolated from actinomycetes strains, Microbacterium proteolyticum LA2(R) and Streptomyces rochei LA2(O), were employed to synthesize silver nanoparticles (AgNPs) at 37 °C for seven days incubation. UV–Vis spectroscopy, TEM, FTIR, and HPLC studies were used for the confirmation of the synthesis of AgNPs. Furthermore, these NPs demonstrated antibacterial and antibiofilm activities against meningitis-causing bacteria. The average size of LA2(R) and LA2(O) isolated secondary metabolites mediated AgNPs was observed to be 27 ± 1and 29 ± 2 nm by TEM analysis. FTIR study of RAgNPs and OAgNPs revealed that presence of peaks with positions of 1637.17 cm1 and 1636.10 cm1 for C=O amide group appearances in the amide I linkage. These NPs were effective against bacterial pathogens such as S. pneumoniae, H. influenzae, and N. meningitidis and confirmed by their MICs, i.e., 109.4, 120.60, and 138.80 μg/ml of RAgNPs and 105.80, 114.40 and 129.06 μg/ml of OAgNPs, respectively. Additionally, the production of biofilms is impeded by these nanoparticles on S. pneumoniae, H. influenzae, and N. meningitidis by 73.14%, 71.89% and 64.81%, respectively. These findings confirm the potential role of synthesized AgNPs against biofilm forming meningitis causing Multidrug resistance (MDR) microbes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Integral University, Protein Research Laboratory, Department of Bioengineering, Lucknow, India (GRID:grid.411723.2) (ISNI:0000 0004 1756 4240)
2 Buraydah Private Colleges, Department of Health Information Management, College of Applied Medical Sciences, Buraydah, Saudi Arabia (GRID:grid.411723.2)
3 Majmaah University, Department of Medical Laboratory Sciences, College of Applied Medical Science, Al-Majmaah, Saudi Arabia (GRID:grid.449051.d) (ISNI:0000 0004 0441 5633)
4 Prince Sattam Bin Abdulaziz University, Department of Pharmaceutical Chemistry, College of Pharmacy, Al-Kharj, Saudi Arabia (GRID:grid.449553.a) (ISNI:0000 0004 0441 5588)
5 University of Tabuk, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Tabuk, Saudi Arabia (GRID:grid.440760.1) (ISNI:0000 0004 0419 5685)